Advanced search

262 Results

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients	30/04	EQ
Newron Pharmaceuticals S p A : announces AGM 2024 results	17/04	PU
Moderna : 2024 Proxy Statement	17/04	PU
Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)	08/04	EQ
Newron presents 2023 financial results and provides 2024 outlook	19/03	EQ
Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement	15/03	EQ
Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million	14/03	EQ
Bugcrowd raises $102 million from General Catalyst, others	12/02	RE
Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)	04/01	EQ
Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide	29/12	EQ
Newron Pharmaceuticals S p A : completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide	29/12	PU
Stellantis Global Chief Marketing Officer Olivier Francois Named as One of Newest Inductees Into AAF Advertising Hall of Fame	30/11	AQ
Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria	09/23/09	EQ
Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress	04/23/04	EQ
Newron Pharmaceuticals S p A : to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress	04/23/04	PU
Nobel in medicine goes to 2 scientists whose work enabled creation of mRNA vaccines against COVID-19	02/23/02	AQ
Newron appoints Margarita Chavez as board advisor	02/23/02	EQ
Newron announces H1 2023 results and provides R&D update	04/23/04	EQ
Newron Pharmaceuticals S p A : announces H1 2023 results and provides R&D update	04/23/04	PU
VMware Names Karen Dykstra as CFO; Zane Rowe to Depart Company ‑ VMware News and Stories	26/23/26	AQ
VMWARE, INC. : Change in Directors or Principal Officers, Financial Statements and Exhibits (form 8-K)	26/23/26	AQ
VMware Names Karen Dykstra as CFO; Zane Rowe to Depart Company	26/23/26	BU
Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)	15/23/15	EQ
MODERNA, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	06/23/06	AQ
Newron to present at the 34th CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)	03/23/03	EQ
Newron announces Senior Management Team changes	02/23/02	EQ
Newron announces AGM 2023 results	18/23/18	EQ
Newron presents six-month interim data from the first 100 patients randomized in study 014/015 at the 31st European Congress of Psychiatry	28/23/28	EQ
Newron reports compelling topline results from all patients in Study 014, its Phase II clinical trial evaluating evenamide as add-on therapy for treatment-resistant schizophrenia	20/23/20	EQ
Newron Pharmaceuticals S p A : to present at the 31st European Congress of Psychiatry	17/23/17	PU
Newron to present at the 31st European Congress of Psychiatry	17/23/17	EQ
Newron announces 2022 financial results and provides outlook for 2023	14/23/14	EQ
Newron Pharmaceuticals S p A : announces 2022 financial results and provides outlook for 2023	14/23/14	PU
Transcript : Vuzix Corporation, Q4 2022 Earnings Call, Mar 01, 2023	02/23/02
Newron reports striking one-year interim efficacy results from its Phase II clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia	16/23/16	EQ
Newron announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia	03/23/03	EQ
Newron Pharmaceuticals S p A : announces striking six-month interim results from its exploratory clinical trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia	03/23/03	PU
WTW announces election of three new Board Directors	09/22/09	AQ
Newron provides H1 2022 results and updates on R&D and business activities	15/22/15	EQ
Newron Pharmaceuticals S p A : provides H1 2022 results and updates on R&D and business activities	15/22/15	PU
VMWARE, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	15/22/15	AQ
Newron extends Senior Management team and strengthens commitment to ESG	01/22/01	EQ
Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology	07/22/07	EQ
Veteran Technology Industry Executive Nicole Anasenes Joins VMware Board of Directors	02/22/02	BU
VMware : Veteran Technology Industry Executive Nicole Anasenes Joins VMware Board of Directors - Form 8-K	02/22/02	PU
Transcript : Moderna, Inc. - Shareholder/Analyst Call	28/22/28
Newron announces AGM 2022 results	05/22/05	EQ
Newron announces 2021 financial results and provides outlook for 2022	15/22/15	EQ
Zorus Raises $9M Series A Funding	09/21/09	PR
Change in Newron Board of Directors	01/21/01	EQ

No results for this search

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer